Efficacy Assessment of CAR-T Cell Therapies in Orthotopic Glioblastoma Xenograft Models Using Bioluminescence Imaging

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Efficacy Assessment of CAR-T Cell Therapies in Orthotopic Glioblastoma Xenograft Models Using Bioluminescence Imaging

Efficacy Assessment of CAR-T Therapies in Orthotopic Glioblastoma Models

CELL & GENE | RNA | BIOLOGICS

Proven Intelligence Accelerating Next-Generation Therapies.

A close-up of a multi-channel pipette dispensing liquid into a microplate in a laboratory setting, with a blue color overlay.

A close-up, detailed shot of a Sartorius Stedim Biotech BIOSTAT STR® single-use bioreactor in a laboratory setting.

Executive Summary

The technical approach for assessing Chimeric Antigen Receptor (CAR)-T cell therapy efficacy in orthotopic glioblastoma xenograft models uses bioluminescence imaging (BLI). This methodology provides longitudinal, quantitative data on tumor burden and therapeutic response, which supports the advancement of complex cell therapies toward IND submission. The process details the development of customized animal models, advanced imaging techniques, and the integration of these services within a GxP-compliant framework to support regulatory filings.

Frequently Asked Questions

    What is the primary advantage of using bioluminescence imaging (BLI) for glioblastoma models?

    BLI allows for non-invasive, longitudinal monitoring of intracranial tumor growth and regression in the same animal over time. This reduces animal usage and provides more robust kinetic data on therapeutic response compared to terminal endpoint analysis.

    How are the glioblastoma cell lines prepared for these models?

    Human glioblastoma cell lines (e.g., U-87 MG) are engineered to stably express a luciferase reporter gene. This allows the tumor cells to produce light upon administration of a luciferin substrate, making them detectable by the imaging system.

    Are these efficacy assessments performed under GxP conditions?

    Early-stage efficacy and pharmacology assessments are typically conducted in non-GxP environments, but all methods and processes are designed with regulatory requirements in mind. This ensures data is captured with high fidelity, and the protocols can be adapted for IND-enabling toxicology programs conducted under GxP conditions in our >100,000 sq ft facility.

    What is the typical timeline for an orthotopic glioblastoma efficacy assessment?

    From model establishment to final data analysis, a typical assessment can range from 60 to 90 days, depending on the specific CAR-T construct, dosing regimen, and the growth kinetics of the selected tumor cell line. This work contributes to an overall 18-24 month timeline to get candidates to IND.

The Challenge of Quantifying CAR-T Efficacy in Solid Tumors

Assessing the in vivo activity of CAR-T cell therapies against solid tumors, particularly within the central nervous system, presents distinct technical hurdles. Unlike hematological malignancies, glioblastoma tumors are not accessible for direct measurement. A tailored preclinical strategy is required to generate definitive data on CAR-T cell trafficking, persistence, and tumor-killing capacity.

A standard, one-size-fits-all preclinical testing template does not exist for these therapies. A science-based, data-driven strategy must be tailored specifically to the asset modality and target indication to produce a data package suitable for regulatory review.

A scientist in a lab coat and gloves looks through a microscope in a laboratory setting, with a blue color overlay.

A scientist pipetting a red liquid into a multi-well plate in a laboratory setting.

Orthotopic Xenograft Models for Glioblastoma

To accurately reflect the clinical indication, human glioblastoma cells expressing luciferase are stereotactically implanted into the brains of immunodeficient rodents. This orthotopic placement recreates the appropriate tumor microenvironment.

  • Cell Line Validation: Prior to implantation, cell lines are confirmed for stable luciferase expression and consistent growth kinetics.

  • Surgical Precision: Stereotactic surgical procedures ensure accurate and reproducible tumor cell implantation into the targeted brain region (e.g., striatum).

  • Model Confirmation: Tumor engraftment and growth are confirmed via baseline BLI before the initiation of CAR-T cell administration.

Model Development and Validation Protocol

This rigorous model development process provides a reliable platform for evaluating therapeutic efficacy.

Learn more about the infrastructure required for next-generation therapeutics in the full-length video: .

A female scientist in a lab coat analyzes complex biological data, including cellular imagery and DNA models, on a computer screen.

A senior scientist with grey hair is mentoring a diverse group of younger scientists or students in a laboratory setting.

Bioluminescence Imaging for Longitudinal Assessment

Following CAR-T cell administration, animals are imaged at regular intervals. The quantitative data derived from BLI provides direct insight into the anti-tumor activity of the therapeutic candidate.

Imaging Parameter Technical Specification Rationale
Modality Bioluminescence Imaging (BLI) Non-invasive, high-throughput, and quantitative.
Substrate D-luciferin Administered systemically prior to each imaging session.
Data Output Photon Flux (photons/sec) Directly correlates with the number of viable tumor cells.
Frequency Bi-weekly or weekly Captures tumor growth kinetics and response dynamics.

This approach generates clear, objective data demonstrating tumor regression, stasis, or progression, forming a core component of the preclinical data package. While the Franklin Biolabs brand launched in 2024, our scientific leadership’s work has contributed to a 100% successful IND rate for sponsors since 2019.

Animal Welfare

All procedures are conducted in compliance with AAALAC and USDA guidelines. Our commitment to animal welfare includes a focus on the 3Rs (Replacement, Reduction, and Refinement) and enhanced housing conditions to promote species-specific behaviors.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Technical Visualization: CAR-T Efficacy Workflow in Glioblastoma Models

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities